WCN26-5384 Managing Fulminant Liver Failure from Anti-Tuberculosis Drug-Induced Hepatotoxicity Using DPMAS: A Case Report

Drug-induced liver injury (DILI) remains one of the most challenging complications in clinical medicine, particularly in regions with high infectious disease burdens where multidrug regimens are often indispensable. Among the most common agents responsible are the first-line anti-tuberculosis (anti-TB) drugs—isoniazid, rifampicin, and pyrazinamide—which are widely used as part of standard treatment protocols for tuberculosis. In the Philippines, where TB remains a major public health concern, DILI poses a substantial clinical problem, contributing to cases of acute liver failure (ALF) that carry high morbidity and mortality (Andrade, 2019).